ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2019
First-in-human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Device therapies in cardiorenal syndrome: an expert review.ESC heart failure · 2026Review
- Sustained Mechanical Occlusion of the Superior Vena Cava Safely Reduces Cardiac Filling Pressures in a Preclinical Model of Heart Failure.Journal of cardiovascular translational research · 2026Article
- Device-driven cyclic compression of the superior vena cava as a preload reduction strategy to improve cardiac function in heart failure: a pilot feasibility study.Scientific reports · 2026Article
- Device-based therapies in cardio-renal syndrome: a pathophysiology-driven approach to a complex bidirectional disease.Frontiers in cardiovascular medicine · 2026Review
- Intermittent, partial occlusion of inferior vena cava for hemodynamic stabilization during OPCAB procedures with left ventricular dysfunction.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Review
- Right ventricular pressure-volume relations and effects of selective vena cava occlusion during cardiopulmonary resuscitation.PloS one · 2025Article
- Cardio-Renal Syndrome: Latest Developments in Device-Based Therapy.Journal of clinical medicine · 2024Review
- Device therapies for heart failure with reduced ejection fraction: a new era.Frontiers in cardiovascular medicine · 2024Review
- Advances in novel devices for the treatment of heart failure.Heart failure reviews · 2023Review
- Transcatheter interventions for heart failure.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Review
- Novel Therapeutic Devices in Heart Failure.Journal of clinical medicine · 2022Review
- Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRIFrontiers in cardiovascular medicine · 2022Review
- Partial vena cava occlusion (VCO) to counteract refractory heart failure: A new era in interventional heart failure strategy.Annals of medicine and surgery (2012) · 2021Review
- Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances.Current cardiology reports · 2020Review
- Intermittent Occlusion of the Superior Vena Cava Reduces Cardiac Filling Pressures in Preclinical Models of Heart Failure.Journal of cardiovascular translational research · 2020Article
- Acute Cardiac Unloading and Recovery: Proceedings of the 4th Annual Acute Cardiac Unloading and REcovery (A-CURE) symposium held on 30 August 2019 in Paris, France.Interventional cardiology (London, England) · 2019Article
- Emerging Device Therapies for Cardiorenal Syndrome.Journal of the Society for Cardiovascular Angiography & InterventionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAcutely decompensated heart failure remains a major clinical problem. Volume overload promotes cardiac and renal dysfunction and is associated with increased morbidity and mortality in heart failure. We hypothesized that transient occlusion of the superior vena cava (SVC) will reduce cardiac filling pressures without reducing cardiac output or systemic blood pressure. The objective of this proof of concept study was to provide initial evidence of safety and feasibility of transient SVC occlusion in patients with acutely decompensated heart failure and reduced ejection fraction. METHODS AND
resultsIn eight patients with systolic heart failure, SVC occlusion was performed using a commercially available occlusion balloon. Five minutes of SVC occlusion reduced biventricular filling pressures without decreasing systemic blood pressure or total cardiac output. In three of the eight patients, a second 10-minutes occlusion had similar hemodynamic effects. SVC occlusion was well-tolerated without development of new symptoms, new neurologic deficits, or any adverse events including stroke, heart attack, or reported SVC injury or thrombosis at 7 days of follow up.
conclusionWe report the first clinical experience with transient SVC occlusion as a potentially new therapeutic approach to rapidly reduce cardiac filling pressures in heart failure. No prohibitive safety signal was identified and further testing to establish the clinical utility of transient SVC occlusion for acute decompensated heart failure is justified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.